Skip to content

International Journal of Drug Policy

ISSN 1873-4758, 0955-3959

82 papers in the library · 1,858 citations · publishing 2006-2026

Papers

Sort Most recent Most cited

Suitability of infrared spectroscopy for drug checking in harm reduction centres.

International Journal of Drug Policy February 2021 Ruben Goncalves, Karine Titier, V Latour et al.

Drug checking is a service for people who use drugs that includes product analysis and an individual interview including results feedback and harm reduction counselling. It uses different analytical methods but few studies demonstrate their value in current practice. The main objective of this work is to compare the analytical performance of IR spectroscopy to laboratory reference method in the...

DOI: 10.1016/j.drugpo.2020.103037 (opens in new tab) Full text (opens in new tab) Drug checking Harm reduction Infrared spectroscopy Qtof

Sociological investigations of human enhancement drugs: The case of microdosing psychedelics

International Journal of Drug Policy January 28, 2021 Dimitrios Liokaftos 17 citations

Microdosing psychedelics is the regular use of sub-perceptive threshold doses of substances such as lysergic acid diethylamide (LSD) and psilocybin ('magic') mushrooms. The phenomenon has attracted increasing public and scientific attention in numerous countries in recent years. This commentary looks at microdosing psychedelics as an emerging facet of human enhancement through drugs. After...

Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences.

International Journal of Drug Policy 2021 Liridona Gashi, Sveinung Sandberg, Willy Pedersen 170 citations

We study the significance of stories about bad trips among users of psychedelics. Drawing on narrative theory, we describe the characteristics of such stories and explore the work they do. In-depth qualitative interviews with 50 Norwegian users of psychedelics. Almost all participants had frightening experiences when using psychedelics and many described these as bad trips. The key feature of a...

Pharmacosex: Reimagining sex, drugs and enhancement

International Journal of Drug Policy November 24, 2020 Leah Moyle, Alex Dymock, Alexandra Aldridge et al. 42 citations

BACKGROUND: The use of drugs in sexual contexts is receiving closer attention in the media, public health bodies and communities than ever before. However, research to date is most often concerned with the sex-related drug use of lesbian, gay, bisexual, transgender and queer (LGBTQ) populations, and particularly men who have sex with men (MSM) engaging in 'chemsex'. Against a backdrop dominated...

DOI: 10.1016/j.drugpo.2020.102943 (opens in new tab) Transgender Pleasure Human sexuality Queer +7

Ibogaine therapy for addiction: Consumer views from online fora.

International Journal of Drug Policy September 1, 2020 Michaela Barber, John Gardner, Michael Savic et al. 16 citations

Background Ibogaine is a psychedelic drug used by for-profit clinics and lay-people to treat addiction, despite some reported fatalities and a lack of rigorous clinical research. Little is known about ibogaine therapy from a consumer perspective. Online discussions generate and disseminate information about ibogaine therapy and provide a window into how people understand ibogaine's risks and...

DOI: 10.1016/j.drugpo.2020.102857 (opens in new tab) Full text (opens in new tab) Online fora Ibogaine therapy ibogaine Ibogaine treatment Ibogaine's use +16

MDMA-related deaths in Australia 2000 to 2018.

International Journal of Drug Policy December 19, 2019 A. Roxburgh, Julia Lappin 43 citations

BACKGROUND MDMA markets have undergone substantial changes internationally, with increasing manufacture of high purity MDMA recorded. This study examined trends in MDMA-related deaths in Australia, investigating characteristics, circumstances and toxicology of these deaths. METHODS Analysis of MDMA-related deaths in Australia between 2001 and 2018, extracted from the National Coronial...

Microdosing psychedelics: Motivations, subjective effects and harm reduction

International Journal of Drug Policy November 25, 2019 Toby Lea, Nicole Amada, Henrik Jungaberle et al. 119 citations

BackgroundIn recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term...

'Never drop without your significant other, cause that way lies ruin': The boundary work of couples who use MDMA together.

International Journal of Drug Policy September 1, 2019 Katie Anderson, Paula Reavey, Zoë Boden 10 citations

MDMA has a variety of pro-social effects, such as increased friendliness and heightened empathy, yet there is a distinct lack of research examining how these effects might intertwine with a romantic relationship. This article seeks to compensate for this absence and explore heterosexual couples' use of MDMA through the lens of the boundaries they construct around these experiences. Three couple...

Psychedelic-assisted therapies: The past, and the need to move forward responsibly

International Journal of Drug Policy May 25, 2019 John Gardner, Adrian Carter, Kerry O’Brien et al. 23 citations

Recent clinical studies illustrate that psychedelics such as LSD and psilocybin may represent much-needed new treatment options for mood disorders and alcohol and other drug use disorders. More clinical studies are required to confirm the safety and efficacy of psychedelic-assisted therapies, but the cultural stigma that has surrounded psychedelics since the 1960s has hindered research. This...

Narrative identity, rationality, and microdosing classic psychedelics

International Journal of Drug Policy May 8, 2019 Megan Webb, Heith Copes, Peter S. Hendricks 75 citations

BackgroundMicrodosing involves ingesting a small dose of a classic psychedelic (e.g., LSD and psilocybin) at regular intervals for prolonged periods. The practice is said to reduce anxiety, improve mood, and offer several creative and practical benefits to users. Using the narrative identity theoretical framework, our aim was to explore the experiences of those who microdosed classic...

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis

International Journal of Drug Policy February 10, 2019 Elena Argento, Kenneth W. Tupper, M. Eugenia Socias 17 citations

The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmacotherapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for innovative interventions...

DOI: 10.1016/j.drugpo.2018.11.006 (opens in new tab) Opioid use disorder Fentanyl Psychological intervention Pharmacotherapy +3

Islam and cannabis: Legalisation and religious debate in Iran.

International Journal of Drug Policy April 9, 2018 Maziyar Ghiabi, Masoomeh Maarefvand, Hamed Bahari et al.

Iran is currently discussing cannabis and opium regulations, which could bring a legalisation of drug consumption through a state supervised system. The article engages with the question of cannabis by looking at the legal interpretation of religious authorities in the Islamic Republic of Iran. The choice of Iran is justified for several reasons: firstly, Iran has a long history of drug use and...

DOI: 10.1016/j.drugpo.2018.03.009 (opens in new tab) Full text (opens in new tab) Humans Legislation, drug Religion and medicine Middle east +5

From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends.

International Journal of Drug Policy December 2017 Marit Edland-Gryt, Sveinung Sandberg, Willy Pedersen

Ecstasy pills with MDMA as the main ingredient were introduced in many European countries in the 1980s, and were often linked to the rave and club scenes. However, use gradually levelled off, in part as a response to increased concerns about possible mental health consequences and fatalities. Extensive use of MDMA now seems to be re-emerging in many countries. In this study, we investigated the...

DOI: 10.1016/j.drugpo.2017.07.030 (opens in new tab) Full text (opens in new tab) Club drug use Ecstasy pills Lay epidemiology MDMA Crystals +2

Nine reasons why ecstasy is not quite what it used to be.

International Journal of Drug Policy November 20, 2017 Jane Mounteney, Paul J Griffiths, Alessandra Bo et al.

This paper explores the recent resurgence in use of ecstasy/MDMA in Europe and highlights keys areas of continuity and divergence between the ecstasy market of the 1990s and the current MDMA market. Based on a scoping study involving a targeted multi-source data collection exercise on MDMA, it highlights nine areas that have undergone some level of change, linked with both supply and demand for...

Psychedelic pleasures: An affective understanding of the joys of tripping.

International Journal of Drug Policy November 1, 2017 Frederik Bøhling

This paper considers the pleasures of psychedelic drugs and proposes a Deleuzian understanding of drugged pleasures as affects. In spite of a large body of work on psychedelics, not least on their therapeutic potentials, the literature is almost completely devoid of discussions of the recreational practices and pleasures of entheogenic drugs. Yet, most people do not use psychedelics because of...

DOI: 10.1016/j.drugpo.2017.07.017 (opens in new tab) Full text (opens in new tab) Affect theory Deleuze Pleasure Psychedelic drugs +1

Online test purchased new psychoactive substances in 5 different European countries: A snapshot study of chemical composition and price.

International Journal of Drug Policy June 1, 2017 Tibor Markus Brunt, Amanda Marie Atkinson, Thomas Nefau et al.

New psychoactive substances (NPS) are on offer worldwide online, in order to shed light on the purity and price of these substances in the European Union, a research collaboration was set up involving France, United Kingdom (UK), the Netherlands, Czech Republic and Poland. Per country, around 10 different NPS were test purchased from different webshops. Then, chemical analysis of NPS was done...

Motivations for new psychoactive substance use among regular psychostimulant users in Australia.

International Journal of Drug Policy May 2017 Rachel Sutherland, Raimondo Bruno, Amy Peacock et al.

Examine the motivations for new psychoactive substance (NPS) use amongst a sample of regular psychostimulant users (RPU) in Australia, and determine whether motivations differ across substances. Data were obtained from 419 RPU interviewed for the 2014 Ecstasy and related Drugs Reporting System who reported lifetime NPS use. Based on the most recent NPS used, motivations for use were rated on an...

Ayahuasca’s entwined efficacy: An ethnographic study of ritual healing from ‘addiction’

International Journal of Drug Policy April 19, 2017 Piera Talin, Emilia Sanabria 101 citations

The ritual use of ayahuasca stands in strong contrast to hegemonic understandings of addiction, paving new ground between the overstated difference between community and pharmacological interventions. The article concludes that fluid, adaptable forms of caregiving play a key role in the success of addiction recovery and that feeling part of a community has an important therapeutic potential.

DOI: 10.1016/j.drugpo.2017.02.017 (opens in new tab) Ayahuasca Addiction Psychological intervention Psychotherapist +2

I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.

International Journal of Drug Policy February 1, 2017 Allison J Matthews, Rachel Sutherland, Amy Peacock et al. 23 citations

Over the past decade, monitoring systems have identified the rapid emergence of new psychoactive substances (NPS). While the use of many NPS is minimal and transitory, little is known about which products have potential for capturing the attention of significant proportions of the drug consuming market. The aim of this study was to explore self-reported experiences of three commonly used NPS...

Medicine, religion and ayahuasca in Catalonia. Considering ayahuasca networks from a medical anthropology perspective

International Journal of Drug Policy October 18, 2016 Ismael Apud, Oriol Romaní 40 citations

Ayahuasca is a psychoactive beverage from the Amazon, traditionally used by indigenous and mestizo populations in the region. Widespread international use of the beverage began in the 1990s in both secular contexts and religious/spiritual networks. This article offers an analysis of these networks as health care systems in general and for the case of Spain and specifically Catalonia, describing...

DOI: 10.1016/j.drugpo.2016.07.011 (opens in new tab) Ayahuasca Medicalization Perspective graphical Medical anthropology +4

The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations

International Journal of Drug Policy March 23, 2016 Christophe Soussan, Anette Kjellgren 152 citations

BACKGROUND: The increasing number of Novel Psychoactive Substances (NPS) constitutes a challenge for public health agencies and researchers worldwide. Scientific studies about NPS and their users are limited and there is a need to explore the general motivations for NPS use but also to examine if and how the motivations differ between substances from separate effect classes. The aim of the...

Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights.

International Journal of Drug Policy March 1, 2016 C. Walsh 37 citations

This paper reimagines drug policy--specifically psychedelic drug policy--through the prism of human rights. Challenges to the incumbent prohibitionist paradigm that have been brought from this perspective to date--namely by calling for exemptions from criminalisation on therapeutic or religious grounds--are considered, before the assertion is made that there is a need to go beyond such reified...

Nod and wave: an Internet study of the codeine intoxication phenomenon.

International Journal of Drug Policy January 2015 Marie Claire Van Hout

The non-medical use of pharmaceutical opioids such as codeine is of increasing public health concern. The aim of the study was to describe codeine intoxication experiences amongst recreational drug users, as posted on public Internet forums. Internet searches were carried out by using the specific key word 'codeine' and in combination with 'experience', 'report', 'trip' and 'forum'. 96 Trip...

Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users

International Journal of Drug Policy July 15, 2014 Hanna Uosukainen, Ulrich Tacke, Adam Winstock 55 citations

BackgroundEvidence regarding MDMA (ecstasy) dependence and the most suitable criteria for its assessment are controversial. This study aimed to assess the prevalence of last year symptoms of dependence upon MDMA compared to cocaine, mephedrone and ketamine among a large global non-treatment seeking sample.MethodsA cross-sectional anonymous online survey was promoted by a UK-based dance music...

Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: a time series analysis.

International Journal of Drug Policy January 2014 Ian Hamilton, Charlie Lloyd, Catherine Hewitt et al.

The UK Misuse of Drugs Act (1971) divided controlled drugs into three groups A, B and C, with descending criminal sanctions attached to each class. Cannabis was originally assigned by the Act to Group B but in 2004, it was transferred to the lowest risk group, Group C. Then in 2009, on the basis of increasing concerns about a link between high strength cannabis and schizophrenia, it was moved...